PrimeC Lowers Neuron-Derived TDP-43, Informing Phase 3 PARAGON Trial in ALS

09 Nov 2026 0 comments

Newly presented biomarker and clinical findings from the phase 2b PARADIGM trial of PrimeC informed the design of the global phase 3 PARAGON trial in ALS.

Source: NeurologyLive Published 08 Nov 2026 Imported 08 Nov 2026 Relevancy: Not reviewed

Read the article

Comments

No comments yet.

Unrestricted

All comments are reviewed before being published. Most comments are approved unless they are clearly inappropriate or unsafe.

Comments

Leave a comment